References:
  1. Smith PF, Dodds M, Bentley D, et al. Dosing will be a key success factor in repurposing antivirals for COVID‐19. Br J Clin Pharmacol . 2020 Apr 17. doi: 10.1111/bcp.14314
  2. Caly L, Druce JD, Catton MG, et al. The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res2020 https://doi.org/10.1016/j.antiviral.2020.104787.
  3. Wagstaff KM, Rawlinson SM, Hearps AC, et al. An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen 2011; 16(2): 192-200
  4. Weil GJ, Bogus J, Christian M, et al. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.PLoS Med 2019;16(6):e1002839.
  5. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002; 42(10): 1122-1133.
  6. U.S. Package Circular: STROMECTOL® (ivermectin). Whitehouse Station, NJ: Merck & Co., Inc., 1998.